Zynerba Pharmaceuticals (ZYNE) Short Interest Ratio & Short Volume

Short interest is the volume of Zynerba Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 5,090,000 shares of ZYNE short. 25.51% of Zynerba Pharmaceuticals' shares are currently sold short. Learn More on Zynerba Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 25.51% of Zynerba Pharmaceuticals' floating shares are currently sold short.

Zynerba Pharmaceuticals saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 5,090,000 shares, a drop of 4.5% from the previous total of 5,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Zynerba Pharmaceuticals currently has issued a total of 53,939,000 shares. Some of Zynerba Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Zynerba Pharmaceuticals currently has a public float of 19,950,000 shares.

25.51% of Zynerba Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Zynerba Pharmaceuticals: Cryoport, Inc. (5.08%), Phathom Pharmaceuticals, Inc. (24.88%), Cartesian Therapeutics, Inc. (24.65%), XOMA Co. (1.36%), 2seventy bio, Inc. (5.79%), Monopar Therapeutics Inc. (1.32%), Aquestive Therapeutics, Inc. (11.93%), Vanda Pharmaceuticals Inc. (7.39%), Emergent BioSolutions Inc. (17.14%), Atea Pharmaceuticals, Inc. (4.46%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($9.07 billion), T-Mobile US, Inc. ($3.71 billion), Charter Communications, Inc. ($3.51 billion), Occidental Petroleum Co. ($2.81 billion), Lululemon Athletica Inc. ($2.35 billion), Tractor Supply ($2.26 billion), Coinbase Global, Inc. ($1.88 billion), Rivian Automotive, Inc. ($1.71 billion), Celsius Holdings, Inc. ($1.67 billion), and Newmont Co. ($1.66 billion). View all of the most shorted stocks.

Short selling ZYNE is an investing strategy that aims to generate trading profit from Zynerba Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Zynerba Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZYNE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZYNE, twice per month. The most recent reporting period available is October, 31 2023.